BRANFORD, Conn. / Oct 20, 2025 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will be participating in the CG MedTech, Diagnostics and Digital Health & Services Forum taking place Thursday, November 20, 2025 at the Westin NY Grand Central.
Jeff Hawkins, CEO, will participate in a Fireside Chat on November 20, 2025, at 3:30 PM ET. He and Jeff Keyes, CFO, will also be available for one-on-one meetings throughout the day. A live and archived webcast of the event will be available in the “Investors” section of the Quantum-Si website under Events & Presentations.
About Quantum-Si Incorporated
Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company’s platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at quantum-si.com or follow us on LinkedIn or X.
| Last Trade: | US$1.27 |
| Daily Change: | 0.05 4.10 |
| Daily Volume: | 5,478,191 |
| Market Cap: | US$248.350M |
November 20, 2025 November 05, 2025 September 23, 2025 September 08, 2025 | |

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load